Lithium Ion

Lithium Ion

SCHEMBL260546

CC12CC(=O)Nc3cccc(c31)N(CC(=O)[O-])C2.[Li+]

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CALCRL Q16602 4/20 0.51
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 4/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
RAB9A P51151 1/20 0.35
CASP3 P42574 1/20 0.34
CASP2 P42575 1/20 0.34
ACE P12821 1/20 0.34
MMP13 P45452 1/20 0.34
GFER P55789 1/20 0.34
MAPT P10636 1/20 0.34
EPHX2 P34913 1/20 0.33
POLB P06746 1/20 0.33
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL261134 0.88 CALCRL (0.51) CALCRLALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL13390206 0.84 CALCRL (0.51) CALCRLALDH1A1KDM4EHTTSMN1; SMN2
Isomer A SCHEMBL13379155 0.70 CALCRL (1.00) CALCRL
Lithium Ion SCHEMBL261118 0.60 CALCRL (0.49) CALCRLCASP3CASP2
SCHEMBL9096429 0.59 CREBBP (0.39) KMT2AMEN1MAPTPPARG
SCHEMBL261467 0.58 GAA (0.44) CALCRLALDH1A1KDM4EKMT2AMEN1
SCHEMBL260249 0.58 CYP19A1 (0.47) MAPTPOLB
Lithium Ion SCHEMBL260924 0.57 CALCRL (0.40) CALCRLALDH1A1
Lithium Ion SCHEMBL259977 0.57 CALCRL (0.44) CALCRLCASP3
SCHEMBL261349 0.57 CALCRL (0.51) CALCRLALDH1A1KDM4EHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163752-B2 Tricyclic anilide heterocyclic CGRP receptor antagonists Merck, Sharp & Dohme Corp. (US) 2012-04-24 US disclosed
US-8133891-B2 Tricyclic anilide spirolactam CGRP receptor antagonists Merck, Sharp & Dohme Corp. (US) 2012-03-13 US disclosed